| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2530528 | Current Opinion in Pharmacology | 2008 | 6 Pages |
Abstract
The first therapeutic aptamer was approved for human use in 2004, and a range of chemical substitutions that improve the drug-like properties of aptamers has recently been shown to increase the utility of this modality. Currently there are both anticoagulant and antithrombotic aptamers in the clinic, and additionally there are a number of earlier stage projects in which a variety of cardiovascular targets are inhibited by specific aptamers and for which a wide range of therapeutic applications has been suggested.
Related Topics
Life Sciences
Neuroscience
Cellular and Molecular Neuroscience
Authors
Anthony D Keefe, Robert G Schaub,